Influenza A virus vaccine - Mucosis

Drug Profile

Influenza A virus vaccine - Mucosis

Alternative Names: FluGEM; Mimopath®-based influenza vaccine - Mucosis

Latest Information Update: 21 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mucosis
  • Developer Centre for Human Drug Research; Mucosis
  • Class Influenza A vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 21 Mar 2016 Phase I development is underway in the Netherlands
  • 10 May 2012 Final immunogenicity and adverse events data from a phase I trial in Influenza virus infection prevention released by Mucosis
  • 10 May 2012 Mucosis and the Centre for Human Drug Research complete a phase I safety and immunogenicity trial in Influenza virus infections prevention in the Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top